Prevention of Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
Status:
Not yet recruiting
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 4 study in which
eligible patients with RADIOLOGICALLY ISOLATED SYNDROME (RIS) (as defined by meeting 2017
McDonald criteria for DIS) will be randomized 1:1 to receive ocrelizumab treatment or placebo
(standard of care).